Literature DB >> 7711420

Comparison of serum fluoride levels after administration of monofluorophosphate-calcium carbonate or sodium fluoride: differences in peak serum concentrations.

L Erlacher1, H Teufelsbauer, P Bernecker, P Pietschmann, M Weissel.   

Abstract

Fluoride salts are widely used in Europe in the treatment of established osteoporosis with crush fractures for their ability to increase trabecular bone mass. However, in the United States fluorides are still regarded as an experimental drug. In a prospective, randomized study we compared the fluoride pharmacokinetics of enteric-coated sodium fluoride and disodium monofluorophosphate calcium carbonate (MFP-Ca) over the period of 76 h. Twenty subjects (12 females, 8 males), aged 35-80 years, free of gastrointestinal disorders, renal impairment, and liver disease and without prior fluoride intake entered the study. Ten subjects received NaF (11.3 mg fluoride) twice a day and the other ten MFP-Ca (13.2 mg fluoride) twice a day. During the study period of 76 h the patient's usual food intake was not changed. Serum fluoride levels were determined using an ion sensitive electrode. After intake of a single drug preparation of MFP-Ca or NaF, MFP-Ca showed a significantly shorter lag time of absorption and a significantly higher maximal serum fluoride concentration than NaF (P < 0.01). A comparison of fluoride cumulative characteristics of both drugs showed virtually identical serum fluoride levels before intake of the morning dose on all 4 study days, whereas serum fluoride concentrations measured 4 h afterwards were significantly higher for MFP-Ca than for NaF. These data provide evidence of high "peak" serum fluoride levels for MFP-Ca, whereas only small peak-to-trough fluctuations are seen for NaF.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7711420     DOI: 10.1007/bf00577760

Source DB:  PubMed          Journal:  Clin Investig        ISSN: 0941-0198


  18 in total

1.  Fluoride bioavailability from slow-release sodium fluoride given with calcium citrate.

Authors:  C Y Pak; K Sakhaee; C Parcel; J Poindexter; B Adams; A Bahar; R Beckley
Journal:  J Bone Miner Res       Date:  1990-08       Impact factor: 6.741

2.  Fluoride treatment for osteoporosis.

Authors:  C Nagant de Deuxchaisnes; J P Devogelaer; F Stein
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

3.  Safe and effective treatment of osteoporosis with intermittent slow release sodium fluoride: augmentation of vertebral bone mass and inhibition of fractures.

Authors:  C Y Pak; K Sakhaee; J E Zerwekh; C Parcel; R Peterson; K Johnson
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

4.  Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis.

Authors:  B L Riggs; S F Hodgson; W M O'Fallon; E Y Chao; H W Wahner; J M Muhs; S L Cedel; L J Melton
Journal:  N Engl J Med       Date:  1990-03-22       Impact factor: 91.245

5.  Fluoride directly stimulates proliferation and alkaline phosphatase activity of bone-forming cells.

Authors:  J R Farley; J E Wergedal; D J Baylink
Journal:  Science       Date:  1983-10-21       Impact factor: 47.728

6.  Pharmacokinetics of fluoride in man after single and multiple oral doses.

Authors:  J Ekstrand; G Alván; L O Boréus; A Norlin
Journal:  Eur J Clin Pharmacol       Date:  1977-12-02       Impact factor: 2.953

7.  Treatment of the vertebral crush fracture syndrome with enteric-coated sodium fluoride tablets and calcium supplements.

Authors:  C Nagant de Deuxchaisnes; J P Devogelaer; G Depresseux; J Malghem; B Maldague
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

8.  Treatment of vertebral osteoporosis with disodium monofluorophosphate: comparison with sodium fluoride.

Authors:  P D Delmas; J Dupuis; F Duboeuf; M C Chapuy; P J Meunier
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

9.  Fluoride bioavailability from immediate-release sodium fluoride with calcium carbonate compared with slow-release sodium fluoride with calcium citrate.

Authors:  K Sakhaee; C Y Pak
Journal:  Bone Miner       Date:  1991-08

10.  Influence of food and antacid administration on fluoride bioavailability from enteric-coated sodium fluoride tablets.

Authors:  P Arnold; M Wermeille; M C Chapuy; J Biollaz; E M Grandjean; J L Schelling; P J Meunier
Journal:  Bone       Date:  1989       Impact factor: 4.398

View more
  1 in total

1.  Parenteral monofluorophosphate (MFP) is a more potent inducer of enamel fluorotic defects in neonatal hamster molars than sodium fluoride.

Authors:  Donacian M Lyaruu; Mark Schoonderwoerd; Dane Tio; Chukan Tse; Theodore J Bervoets; Pamela DenBesten; Antonius L J J Bronckers
Journal:  Odontology       Date:  2013-06-21       Impact factor: 2.634

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.